Genzyme Corp.

Clolar wins FDA approval for common pediatric leukemia

Published in Lab Business Week, January 30th, 2005

Genzyme Corp. (GENZ) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Clolar (clofarabine) for the treatment of children with refractory or relapsed acute lymphoblastic leukemia (ALL).

Clolar is the first new leukemia treatment approved specifically for children in more than a decade. Given the unmet need for new treatment options in this seriously ill patient population, Genzyme expects to make Clolar commercially available as quickly as possible in January.

"FDA approval of Clolar is a welcome sign that industry and the agency are beginning to act on the needs of children with cancer very early in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2005-01-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry